Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
Consented for cardiopulmonary bypass surgery for cardiac reason
Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language
Know genetic life limiting conditions
Syndrome patients who are scheduled or highly likely to be operated on more than one organ
Body weight at time of surgery less than 2.5 kg
Being recruited and enrolled for an interventional study protocol
All patients in defined age scheduled for congenital cardiac surgery
Case-only
Prospective
Not listed
Surrogates of Heart Failure
Correlation of sST2 Levels with compound outcome of number of events of combined events of Death, need for MCS (Mechanical Circulatory Support) or Heart Transplantation
30 day Mortality
Number of early deaths (30 days post surgery)
Overall Length of Stay
Time between operation and discharge from hospital
Length of intubation
Days necessary to wean patient from mechanical ventilatory support post surgery.
Length of Stay on ICU
Time between operation and discharge from the intensive care unit (ICU)
Click on the lead sponsor to view all of their trials.
Martin Schweiger
Lead sponsor
University Children's Hospital, Zurich
Sponsor institution
University Children's Hospital, Zurich
Collaborator
